Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

@article{Grant2010RomidepsinAN,
  title={Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.},
  author={Cliona Grant and Fahd Rahman and Richard L. Piekarz and Cody J Peer and Robin Frye and Robert W. Robey and Erin R. Gardner and William D. Figg and Susan E Bates},
  journal={Expert review of anticancer therapy},
  year={2010},
  volume={10 7},
  pages={997-1008}
}
Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known. Romidepsin induces long-lasting responses. The side-effect profile is similar to that… CONTINUE READING